Fig. 2

Changes in (A) BMI, (B) AST, (C) ALT, and (D) GGT from baseline after 12 and 24 weeks in the PIO, EMPA, and combination groups. E Proportion of patients with a relative reduction ≥ 50% in liver fat, a relative reduction ≥ 30% or an absolute reduction ≥ 5% in liver fat, and a relative reduction ≥ 30% in liver fat and ≥ 20% in liver stiffness at 24 weeks. Liver fat and stiffness were evaluated using MRI-PDFF and MRE, respectively (E). ^*P < 0.05 from baseline (A–D). ^#P < 0.05 vs. PIO monotherapy (E). ^*P < 0.05 vs. EMPA monotherapy (E). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; EMPA, empagliflozin; GGT, gamma-glutamyl transferase; PIO, pioglitazone